Literature DB >> 10130844

Cost of illness studies in health care: a comparison of two cases.

A Ament1, S Evers.   

Abstract

Cost of illness (COI) studies describe the economic burden of disease on society. In this article a standard procedure for a COI study is developed, including the explicit definition of the disease, choice of relevant variables and appraisal of direct and indirect costs. COI studies can be incidence-based or prevalence-based. The adjustment of cost figures for time preferences and the performance of a sensitivity analysis are presented. The standard methodology is applied to diseases in two different areas. The first disease category is dyspepsia, a complaint with a rather somatic background. The second is schizophrenia, a mental syndrome. In performing COI studies in practice, however, researchers are forced to deviate, in many aspects, from the theoretical standards. In this article these choices, and the reasons behind these choices, are explained. Furthermore, we discuss certain problems regarding the reluctance to make a diagnosis regarding certain diseases, the reliability and the validity of the sources used and the absence of certain figures. The value of the information derived from COI studies for policy-making is assessed.

Entities:  

Mesh:

Year:  1993        PMID: 10130844     DOI: 10.1016/0168-8510(93)90076-2

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  21 in total

Review 1.  Economic note: cost of illness studies.

Authors:  S Byford; D J Torgerson; J Raftery
Journal:  BMJ       Date:  2000-05-13

2.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 3.  The economic cost of epilepsy: a review.

Authors:  M Brunetti; E Pagano; L Garattini
Journal:  Ital J Neurol Sci       Date:  1998-04

Review 4.  Cost of lung cancer: a methodological review.

Authors:  Laurent Molinier; Christophe Combescure; Cristos Chouaïd; Jean-Pierre Daurès; Bruno Housset; Didier Fabre; Alain Grand; Alain Vergnenègre
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  Preventing ischaemic heart disease in one general practice: from one patient, through clinical audit, needs assessment, and commissioning into quality improvement.

Authors:  M Pringle
Journal:  BMJ       Date:  1998-10-24

6.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

7.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

Review 8.  Economic evaluations of type II diabetes.

Authors:  B Leese
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

Review 9.  Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

Authors:  K G Terkelsen; A Menikoff
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 10.  Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Authors:  Huajie Jin; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.